Cyril Fauriat

Marseille, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications

Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AML.

Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AML.

Journal: Blood advances
Published: September 21, 2023

Downregulation of stromal syntenin sustains AML development.

Downregulation of stromal syntenin sustains AML development.

Journal: EMBO molecular medicine
Published: February 15, 2023

Adhesion Molecules Involved in Stem Cell Niche Retention During Normal Haematopoiesis and in Acute Myeloid Leukaemia.

Adhesion Molecules Involved in Stem Cell Niche Retention During Normal Haematopoiesis and in Acute Myeloid Leukaemia.

Journal: Frontiers in immunology
Published: August 10, 2021

Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia.

Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia.

Journal: Frontiers in immunology
Published: June 25, 2021

High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome.

High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: May 29, 2021

Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor.

Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor.

Journal: Cancers
Published: April 23, 2021

Correction: NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.

Correction: NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.

Journal: Oncotarget
Published: September 20, 2019

Vitamin D Controls Tumor Growth and CD8+ T Cell Infiltration in Breast Cancer.

Vitamin D Controls Tumor Growth and CD8+ T Cell Infiltration in Breast Cancer.

Journal: Frontiers in immunology
Published: March 15, 2019

Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.

Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.

Journal: Frontiers in immunology
Published: March 01, 2018

JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid Leukemia.

JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid Leukemia.

Journal: Cancer research
Published: May 02, 2017

NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.

NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.

Journal: Oncotarget
Published: January 30, 2017

NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML.

NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML.

Journal: Oncoimmunology
Published: January 09, 2017
Showing 1-12 of 26

Last Updated: 09/26/2026